Viridian Therapeutics, Inc.
VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the trā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$27.44
Price-0.22%
-$0.06
1Y
Price
Market Cap
$2.228b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-133477.3%
EBITDA Margin-134313.3%
Net Profit Margin-100553.3%
Free Cash Flow MarginRevenue
$305k
+1.0%
1y CAGR-28.4%
3y CAGR-31.3%
5y CAGREarnings
-$344.061m
-27.4%
1y CAGR-43.5%
3y CAGR-47.1%
5y CAGREPS
-$3.83
+3.8%
1y CAGR-2.3%
3y CAGR+8.6%
5y CAGRBook Value
$515.169m
$582.324m
Assets$67.155m
Liabilities$21.341m
DebtDebt to Assets
3.7%
-0.1x
Debt to EBITDAFree Cash Flow
-$309.599m
-33.0%
1y CAGR-51.5%
3y CAGR-56.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company